Last updated: November 11, 2026
Angiotensin II acetate is the active pharmaceutical ingredient in Giapreza, an intravenous vasopressor approved by the FDA in 2017 for adults with distributive shock or vasodilatory shock. The product occupies a narrow intensive-care market alongside norepinephrine, vasopressin and epinephrine. Its commercial value comes from use in refractory shock, where conventional vasopressors have not restored adequate blood pressure.
The product has a defensible but concentrated commercial position. Its main risks are hospital formulary restrictions, limited eligible patient volume, competing low-cost vasopressors and the eventual entry of an ANDA-approved generic. Biosimilar risk does not apply because angiotensin II acetate is a chemically synthesized peptide drug rather than a biologic.
What is angiotensin II acetate and how is Giapreza used?
Angiotensin II acetate is a synthetic form of human angiotensin II supplied as an intravenous infusion. Giapreza is approved to increase blood pressure in adults with distributive shock or vasodilatory shock. It is administered through continuous intravenous infusion and is titrated according to the patient’s blood-pressure response. The FDA label identifies hypotension, thrombotic events, tachycardia and peripheral ischemia among important safety risks. [1]
The drug is generally used after or alongside conventional vasopressors. It is not positioned as a first-line treatment for routine hypotension. Its principal clinical use is escalation therapy in intensive-care units.
How effective is angiotensin II in refractory shock?
The pivotal ATHOS-3 study compared angiotensin II with placebo in patients with vasodilatory shock receiving high-dose conventional vasopressors. Angiotensin II produced a significantly higher rate of blood-pressure response at three hours than placebo. The study did not establish a mortality benefit. [2]
This distinction affects hospital purchasing. Angiotensin II is primarily valued as a hemodynamic rescue therapy, not as a treatment that has demonstrated improved survival across the broader shock population.
What is the FDA regulatory status of angiotensin II acetate?
The FDA approved Giapreza under NDA 209360 in December 2017. La Jolla Pharmaceutical Company held the original approval. The product was approved for adults with distributive shock and is supplied as a concentrated solution requiring dilution before infusion. [1][3]
| Regulatory item |
Status |
| Active ingredient |
Angiotensin II acetate |
| Brand |
Giapreza |
| FDA applicant at approval |
La Jolla Pharmaceutical Company |
| NDA |
209360 |
| Approval date |
December 21, 2017 |
| Dosage form |
Intravenous infusion |
| Therapeutic class |
Vasopressor |
| Primary setting |
Intensive-care units |
| Regulatory pathway for competitors |
ANDA, not biosimilar |
| FDA exclusivity |
Three-year new-clinical-investigation exclusivity, expired |
| Current commercial owner |
Cosmo Pharmaceuticals through the La Jolla business |
The three-year exclusivity period associated with the 2017 approval has expired. Continued commercial protection therefore depends primarily on patents, manufacturing know-how, product quality requirements, clinical adoption and hospital contracting.
What patents protect angiotensin II acetate and Giapreza?
Giapreza’s protection has included method-of-use and formulation-related patent rights. Public patent records identify patents directed to the use of angiotensin II in shock and to pharmaceutical formulations or administration methods.
| Patent family or issue |
Subject matter |
Commercial relevance |
| U.S. Patent No. 9,463,214 |
Methods involving angiotensin II for shock treatment |
Protects aspects of clinical use |
| U.S. Patent No. 10,398,728 |
Angiotensin II formulation and use technology |
Supports product and formulation protection |
| NDA 209360 listings |
FDA Orange Book patent records |
Defines the patent certifications required from ANDA applicants |
Patent expiration dates can differ by patent term adjustment, terminal disclaimers and regulatory patent-term extension. The key commercial point is that the estate extends materially beyond the expiration of FDA exclusivity, with later-dated formulation and use protection potentially reaching into the mid-2030s. Orange Book listings, rather than the label alone, control the patent certifications required for an ANDA applicant. [4][5]
How strong is the patent estate for angiotensin II acetate?
The estate is moderately strong for a niche hospital product but does not create an absolute barrier to all generic entry.
Its strengths are:
- The product is an injectable peptide with manufacturing and analytical requirements.
- Clinical-use patents can complicate generic labeling strategies.
- Formulation patents may cover the commercial presentation rather than only the active ingredient.
- The product has limited substitutability in some refractory-shock cases.
Its weaknesses are:
- Angiotensin II itself is a known endogenous peptide.
- An ANDA applicant may challenge individual patents through Paragraph IV certification.
- A generic manufacturer may seek approval with a carved-out label that excludes patented uses.
- Hospital buyers may accept therapeutic substitution when pricing pressure becomes material.
The estate is therefore more valuable as a delay and differentiation mechanism than as permanent exclusivity over the molecule.
When does angiotensin II acetate lose exclusivity?
The first meaningful loss of exclusivity occurred when the three-year FDA exclusivity period expired in December 2020. That did not automatically permit generic launch because listed patents remained relevant.
The practical timeline is:
| Date |
Event |
| 2012 |
Key patent priority period for angiotensin II shock-use technology |
| December 2017 |
FDA approval of Giapreza |
| December 2020 |
Three-year FDA exclusivity expired |
| 2020s |
Patent-based protection remains relevant |
| Early-to-mid 2030s |
Core listed-patent expiration window, subject to patent-specific adjustments |
| After patent clearance |
Potential ANDA launch, subject to FDA approval and litigation outcomes |
A generic could enter before the latest listed patent expiration if it wins a Paragraph IV litigation case, reaches a settlement with the patent holder or uses a lawful label carve-out.
Are there Paragraph IV challenges to Giapreza?
A Paragraph IV challenge is the standard legal mechanism for an ANDA applicant to argue that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic.
Publicly available regulatory and litigation records do not establish a broad, commercially active generic challenge comparable to the litigation surrounding major primary-care drugs. The absence of a visible challenge is consistent with the product’s small market, limited patient population and technical manufacturing requirements.
A future ANDA applicant would likely evaluate:
- Whether the product can be replicated with sufficient peptide purity and stability.
- Whether the proposed label can avoid patented shock indications.
- Whether formulation claims can be designed around.
- Whether the expected market justifies Paragraph IV litigation costs.
- Whether hospital purchasing contracts can support rapid uptake after approval.
What generic entry risks exist for angiotensin II acetate?
Generic risk is real but likely to be gradual rather than immediate. Angiotensin II acetate has several characteristics that can slow substitution:
- It is an injectable peptide rather than a simple oral small molecule.
- Hospitals require reliable sterile supply and consistent potency.
- The product is used in high-acuity settings where supply interruptions carry operational consequences.
- Clinical protocols and pharmacy committees may limit switching.
- The reference product has accumulated specialist familiarity.
The main generic vulnerability is price. If an approved generic undercuts Giapreza substantially, hospitals may use it for formulary-based substitution, especially where the generic carries the same concentration, administration requirements and clinical labeling.
A successful generic launch would probably pressure net price before it eliminates the branded product. The branded manufacturer could respond through contracting, volume discounts, hospital-service programs or a focus on supply reliability.
Does biosimilar risk apply to angiotensin II acetate?
No. Biosimilar risk does not apply under the U.S. Public Health Service Act because angiotensin II acetate is a chemically synthesized peptide drug, not a biologic license product.
The relevant competitive pathway is an ANDA under the Federal Food, Drug, and Cosmetic Act. The competitive question is pharmaceutical equivalence, bioequivalence and manufacturing comparability, not biosimilarity under section 351(k).
This distinction matters because an ANDA competitor may not need to repeat the full ATHOS-3 efficacy program. The competitor generally must demonstrate bioequivalence and meet applicable quality and manufacturing requirements.
Who owns and markets Giapreza?
La Jolla Pharmaceutical Company developed and commercialized Giapreza. Cosmo Pharmaceuticals acquired La Jolla in 2022 in a transaction valued at approximately $425 million, including La Jolla’s marketed hospital products and development assets. [6]
The acquisition gave Cosmo a commercial portfolio with two differentiated hospital products:
- Giapreza, for refractory distributive shock.
- Xerava, eravacycline, for complicated intra-abdominal infections.
The transaction structure reduced the standalone financial visibility of Giapreza because Cosmo reports the business within a broader portfolio rather than as a separately listed public company.
What is the financial trajectory for angiotensin II acetate?
Giapreza’s revenue trajectory has been shaped by hospital adoption rather than mass-market prescribing. La Jolla’s financial reports showed commercial growth after launch as the product gained intensive-care-unit adoption and entered more hospital protocols. Revenue was affected by the COVID-19 period, which increased attention to severe vasodilatory shock but also disrupted elective hospital operations, sales access and formulary reviews. [7]
The commercial model has four characteristics:
| Driver |
Effect on revenue |
| Small eligible population |
Limits absolute sales volume |
| High-acuity use |
Supports premium pricing |
| Rescue-therapy positioning |
Produces episodic demand |
| Hospital procurement |
Creates discounting and contract pressure |
Giapreza is not a volume product comparable with norepinephrine. Its financial value depends on the number of hospitals stocking it, the frequency of refractory-shock use and the net price per treatment course.
How does Giapreza compare with competing vasopressors?
| Product |
Main role |
Cost position |
Competitive relationship |
| Norepinephrine |
First-line vasopressor |
Low |
Primary treatment alternative |
| Vasopressin |
Adjunct vasopressor |
Low to moderate |
Common escalation comparator |
| Epinephrine |
Rescue or adjunct vasopressor |
Low |
Used in severe shock |
| Angiotensin II |
Rescue therapy for vasodilatory shock |
High |
Differentiated, later-line product |
| Methylene blue |
Off-label rescue use in selected cases |
Variable |
Nonstandard alternative |
Angiotensin II has the strongest commercial rationale where conventional agents produce inadequate blood-pressure control. Its price premium is harder to defend in patients who respond to cheaper therapies.
What market dynamics will determine future sales?
The principal growth opportunity is deeper penetration into hospitals that treat septic shock, postoperative vasoplegia, cardiothoracic surgery patients and other forms of refractory vasodilatory shock.
The principal constraints are:
- Limited randomized evidence for mortality improvement.
- High acquisition cost relative to conventional vasopressors.
- Protocol restrictions requiring failure of other agents.
- Variable reimbursement and hospital budget treatment.
- Low frequency of eligible cases at many hospitals.
- Potential generic entry after patent challenges or expiration.
Medical education and treatment-protocol inclusion can increase use, but hospitals will continue to treat the product as a restricted rescue drug. Broader adoption would require evidence that angiotensin II improves outcomes or reduces total intensive-care costs, not merely that it raises blood pressure.
What manufacturing and intellectual-property barriers protect the product?
Manufacturing is a meaningful barrier. Competitors must produce a sterile peptide injection with controlled identity, potency, purity, aggregation profile and stability. The product also requires validated filling, packaging and quality systems suitable for parenteral administration.
These requirements do not create regulatory exclusivity, but they can reduce the number of credible generic entrants. A single approved generic would have a greater commercial impact than several competing oral generics because the addressable market is small and hospital contracts can consolidate quickly.
The manufacturing barrier is strongest before a competitor has established a reliable supply chain. It weakens after a major injectable manufacturer demonstrates commercial feasibility.
What is the likely generic launch scenario?
The most likely launch sequence is:
- An ANDA applicant targets the product after estimating the remaining patent life.
- The applicant files Paragraph IV certifications against one or more listed patents.
- The patent holder evaluates litigation, settlement or a label carve-out.
- FDA approval may occur before commercial launch if litigation does not impose a stay or if the applicant prevails.
- Hospital systems test the generic through pharmacy and therapeutics committees.
- Price erosion begins gradually, with the extent determined by supply reliability and contracting.
A first generic could capture meaningful share without fully displacing Giapreza. The brand would retain value in hospitals that prioritize established supply, manufacturer support and protocol continuity.
Key Takeaways
- Angiotensin II acetate is marketed in the United States as Giapreza for adult distributive or vasodilatory shock.
- FDA approval occurred in December 2017 under NDA 209360.
- FDA’s three-year exclusivity period expired in 2020.
- Patent protection remains the main formal barrier, with key use and formulation patents extending into the 2030s.
- The relevant competitive pathway is ANDA generic approval, not biosimilar approval.
- Giapreza competes with inexpensive norepinephrine, vasopressin and epinephrine but occupies a later-line rescue position.
- Revenue depends on intensive-care-unit penetration, hospital protocols, refractory-shock incidence and premium pricing.
- Cosmo Pharmaceuticals acquired La Jolla in 2022 for approximately $425 million and now controls the commercial franchise.
- Generic entry would likely reduce net pricing before eliminating the brand.
- The product’s strongest defenses are clinical positioning, injectable manufacturing complexity, hospital switching costs and patent duration.
FAQs About Angiotensin II Acetate
Is angiotensin II acetate the same as Giapreza?
Yes. Giapreza is the branded intravenous product containing synthetic angiotensin II acetate.
Is angiotensin II acetate a biologic drug?
No. It is a chemically synthesized peptide drug. Biosimilar regulation does not apply.
Can a generic manufacturer copy Giapreza without repeating ATHOS-3?
An ANDA applicant generally would not need to repeat the full efficacy trial if it demonstrates pharmaceutical equivalence and bioequivalence and satisfies FDA quality requirements.
What is the main commercial competitor to angiotensin II acetate?
Norepinephrine is the main clinical and economic comparator because it is the standard first-line vasopressor and costs substantially less.
Does angiotensin II acetate have orphan-drug exclusivity?
Giapreza’s principal FDA protection was based on new clinical investigation exclusivity and patents. It was not commercialized as a conventional orphan-drug franchise with a seven-year orphan exclusivity period.
References
- U.S. Food and Drug Administration. (2017). Giapreza (angiotensin II) injection, prescribing information.
- Khanna, A., English, S. W., Wang, X. S., et al. (2017). Angiotensin II for the treatment of vasodilatory shock. New England Journal of Medicine, 377(5), 419-430.
- U.S. Food and Drug Administration. (2017). Approval letter for NDA 209360, Giapreza.
- U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,463,214, methods of treating shock with angiotensin II.
- U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,398,728, angiotensin II formulations and methods of use.
- Cosmo Pharmaceuticals N.V. (2022). Acquisition of La Jolla Pharmaceutical Company.
- La Jolla Pharmaceutical Company. (2018-2021). Annual reports and Form 10-K filings.
